COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR TREATING CANCER

Abstract: the present disclosure relates to methods for inhibiting the growth of a tumor in a patient in need thereof. the methods comprise administering to the patient an oncolytic virus in combination with a therapeutically effective amount of a pd-1 inhibitor (e.g., cemiplimab or a bioequivalent thereof) and optionally, a therapeutically effective amount of a ctla-4 inhibitor (e.g., ipilimumab or a bioequivalent thereof). in some embodiments, the administration of the combination results in enhanced tumor inhibition as compared to administration of either antibody or the virus alone. in some embodiments, the oncolytic virus is a recombinant vesicular stomatitis virus (vsv), such as vv1.

Inventor(s): Giuseppe Gullo, Stephen J. Russell

CPC Classification: A61K35/768 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250152643